-+ 0.00%
-+ 0.00%
-+ 0.00%

Atrium Therapeutics posts investor presentation on precision RNA medicines for cardiac disease

PUBT·08/13/2026 21:08:12
Listen to the news
Atrium Therapeutics posts investor presentation on precision RNA medicines for cardiac disease
  • Atrium Therapeutics highlighted ATR1072, an RNA-targeting program for PRKAG2 syndrome, a genetic cardiomyopathy linked to arrhythmias and cardiomyopathy.
  • Initial prevalence estimate of 1,000-2,000 PRKAG2 syndrome patients described as conservative, based on published literature.
  • Early lab outreach identified close to 2,000 individuals with a PRKAG2 mutation from a subset of engaged genetic-testing providers.
  • Preclinical data showed PRKAG2 mRNA reduction at day 28 in a mouse model, with improvements in diastolic function measures at 24 weeks.
  • Monkey studies cited target knockdown in heart tissue, with 9-month repeat-dose toxicity study showing no dose-limiting toxicity at highest dose tested.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrium Therapeutics Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.